EULAR 2018 Highlights

yannickelm

Enhancing knowledge of the clinical

importance of cytokine signalling

The Cytokine Signalling Forum

www.cytokinesignalling.com

EULAR 2018

Conference Highlights

Find us at Publishers’ Corner

Developed under

the auspices of the

University of Glasgow

Register for all this FREE content at

www.cytokinesignalling.com


Steering Committee

Professor Iain B. McInnes

University of Glasgow,

UK

CHAIR

Chairman’s Welcome

Professor Johannes W.J. Bijlsma

University Medical Centre,

Utrecht, The Netherlands

Professor Cem Gabay

University Hospitals of Geneva,

Switzerland

Professor Ahmet Gül

Istanbul University,

Turkey

Professor Peter Nash

University of Queensland,

Brisbane, Australia

Professor Georg Schett

University of Erlangen-Nuremberg,

Erlangen, Germany

Professor Maurizio Cutolo

University of Genova,

Italy

Professor Juan J. Gómez-Reino

University Hospital,

Santiago de Compostela, Spain

Professor Pierre Miossec

Hôpital Edouard Herriot, Lyon,

France

Professor John J. O’Shea

NIAMS, Maryland,

USA

Professor Tsutomu Takeuchi

Keio University, Tokyo, Japan

Dear CSF Member,

Welcome to our selection of EULAR 2018 abstracts and ‘Chairman’s picks’.

There continues to be considerable data published on JAK inhibition, with differences in the JAK-STAT signalling

pathway in synovial fibroblasts analysed in different joints [OP0165], and the results of a systematic review and metaanalysis

of Phase 2 and 3 JAK inhibitor studies presented for the risk of patients developing malignancies or serious

infections [OP0032].

It is exciting to see the Phase 3 data for upadacitinib: Burmester et al share the results from patients with an inadequate

response to csDMARDs [OP0036]; Genovese et al, present the safety and efficacy of upadacitinib in bDMARD

inadequate responders [SAT0219]; and Smolen et al evaluate updacitinib as monotherapy [OP0035]. We also see the

results of a Phase 2b/3 study of upadactinib in Japanese patients [SAT0257].

Tofacitinib continues to be prominent this year: data from the ORAL Strategy trial are presented, including the impact

of glucocorticoids on tofacitinib efficacy and safety [SAT0247], and the effect of live zoster vaccination [SAT0220]; while

Kaine et al present data on tofacitinib discontinuation and re-initiation in long-term extension studies [OP0037]. Specific

considerations include a comparison of the effectiveness of tofacitinib and bDMARDs in clinical practice [AB0485],

improvements in left ventricular mass and cardiac output [AB0489]; and identification of subgroups, which could be used

to develop personalised treatment algorithms [SAT0217].

Baricitinib shows interesting and varied data, with post hoc analyses from Phase 3 trials examining the impact of

controlling disease activity on physical function, and pain [AB0258]. The effects of dose reduction are investigated

[SAT0253] and hepatitis B reactivation is examined [FRI0077]; efficacy and safety of baricitinib are reported from the

Phase 3 study RA-BALANCE, which enrolled patients in China, Argentina and Brazil [SAT0218].

Beyond RA, there are data in psoriatic arthritis (PsA); the effects of tofacitinib on several composite endpoint measures

are presented from OPAL Broaden and Beyond [THU0323]; and efficacy analysed by background methotrexate dose

[AB0902], and by baseline demographics, disease activity and concomitant medications [AB0921]. The efficacy and

safety of tofacitinib in patients with or without metabolic syndrome are also compared [SAT0317]. The safety, tolerability

and efficacy of tofacitinib over 36 months are presented from the ongoing OPAL Balance study [SAT0293]. Also of

interest is an evaluation of the effect of tofacitinib on the ability of monocytes to differentiate into dendritic cells, an

important step in innate immunity [AB0046].

Within the following pages, we share our selection of the EULAR 2018 highlights including my ‘Chairman’s picks’. As

always, thank you for your continued support, and we hope you enjoy your time at EULAR 2018!

Yours,

DEVELOPMENT PARTNERS

Professor Kevin Winthrop

Oregon Health and Science

University, USA

Professor Iain McInnes


Key Presentations

Wednesday, June 13, 2018

ORAL PRESENTATIONS

RA therapy - new molecules and new

strategies

Auditorium / Balcony – 16:15 - 17:45

OP0032


Malignancies and Serious Infections in

Randomized Controlled Trials of Janus Kinase

Inhibitors in Patients with Rheumatoid Arthritis: A

Systematic Review and Meta-Analysis

OP0035 Upadacitinib as Monotherapy: A Phase 3

Randomized Controlled Double-Blind Study in

Patients with Active Rheumatoid Arthritis and

Inadequate Response to Methotrexate

OP0036 A Phase 3 Randomized, Placebo-Controlled,

Double-Blind Study of Upadacitinib (ABT-494), A

Selective JAK-1 Inhibitor, in Patients with Active

Rheumatoid Arthritis with Inadequate Response

to Conventional Synthetic DMARDs

OP0037 Efficacy of Tofacitinib After Temporary

Discontinuation in Patients with Rheumatoid

Arthritis: Analysis of Data from Open-Label

Long-Term Extension Studies

Thursday, June 14, 2018

ORAL PRESENTATIONS

Fires and firefighters: switching the

immune system on and off

Emerald – 10:15 - 11:45

OP0165


Joint-Specific Differences in the Activation of the

JAK-Stat Pathway in Rheumatoid Arthritis

Thursday, June 14, 2018

POSTERS

THU0096

THU0106

THU0109

THU0323


A MAPK Activated Kinase 2 Inhibitor

Attenuates Inflammatory and Destructive

Arthritis in Human Ex Vivo Models

Converting Patient-Reported Outcome

Measures of Fatigue and Pain to PROMIS

Scores: Data from Phase 3 Baricitinib

Rheumatoid Arthritis Trials

Autoantibody Profiling for Response to

Baricitinib in Patients with Rheumatoid Arthritis

and No or Limited Exposure to Methotrexate

Tofacitinib Improves Composite Endpoint

Measures of Disease in Patients with

Psoriatic Arthritis

Friday, June 15, 2018

POSTERS

FRI0013

FRI0077


FRI0098

FRI0099

Converting Patient-Reported Physical Function

Outcomes Scores to PROMIS Metric Scores in

Phase 3 Trials of Baricitinib in Rheumatoid Arthritis

Hepatitis B Virus Reactivation in Patients with

Rheumatoid Arthritis Treated with Baricitinib:

Post-Hoc Analysis from Clinical Trials

Hepatic Safety in Patients with Rheumatoid

Arthritis who Received Isoniazid for Latent

Tuberculosis: Post-Hoc Analysis from Phase 3

Baricitinib Studies

Liver Enzyme Abnormalities After Tofacitinib

Treatment in Patients with Hepatic Steatosis

from the Rheumatoid Arthritis, Psoriatic Arthritis

and Psoriasis Clinical Programmes

Saturday, June 16, 2018

POSTERS

SAT0089

SAT0177

SAT0221

SAT0236

SAT0239

SAT0243

SAT0244

SAT0247


Initiating Tofacitinib in a Treat to Target Strategy

for Rheumatoid Arthritis Leads to Blunted Multi-

Biomarker Disease Activity Scores as Compared

to Anti-Tumor Necrosis Factor Agents

Real-World Interruptions in Janus Kinase

Inhibitor Therapy Observed among Biologic-

Naïve and Biologic-Experienced Rheumatoid

Arthritis Patients

Effect of Tofacitinib on Reducing Pain in Patients

with Rheumatoid Arthritis, Psoriatic Arthritis and

Ankylosing Spondylitis

Long-Term Safety and Efficacy of Upadacitinib

(ABT-494), An Oral JAK-1 Inhibitor in Patients

with Rheumatoid Arthritis in an Open Label

Extension Study

Rapid Response with Upadacitinib Treatment

in Patients with Rheumatoid Arthritis and an

Inadequate Response to csDMARDs or bDMARDs

Incidence of Thromboembolic Events in the

Tofacitinib Rheumatoid Arthritis, Psoriasis,

Psoriatic Arthritis and Ulcerative Colitis

Development Programmes

Impact of 12 Weeks of Upadacitinib Treatment

on Individual and Composite Disease Measures

in Patients with Rheumatoid Arthritis and

Inadequate Response to Conventional Synthetic

or Biologic DMARDs

Impact of Glucocorticoids on Efficacy

and Safety of Tofacitinib with and without

Methotrexate and Adalimumab with

Methotrexate for Rheumatoid Arthritis: Results

from a Phase 3b/4 Randomised Trial

SAT0252

SAT0253


SAT0254

SAT0255

SAT0256

SAT0257


SAT0293


SAT0317


SAT0330

Clinical and Functional Response to Tofacitinib

and Adalimumab in Patients with Rheumatoid

Arthritis: Probability Plot Analysis of Results from

the ORAL Strategy Trial

Dose Reduction of Baricitinib in Patients with

Rheumatoid Arthritis Achieving Sustained

Disease Control: Results of a Prospective Study

Upadacitinib Improves Patient-Reported

Outcomes in Patients with Rheumatoid Arthritis

and Inadequate Response to Conventional

Synthetic Disease-Modifying Anti-Rheumatic

Drugs: Results from SELECT-NEXT

Patient Reported Outcomes of Upadacitinib:

Results from Biologic Inadequate Responders

(SELECT BEYOND Phase III Trial)

Tofacitinib with and without Methotrexate Versus

Adalimumab with Methotrexate for the Treatment

of Rheumatoid Arthritis: Patient-Reported

Outcomes from a Phase 3b/4 Randomised Trial

A Phase 2b/3 Randomized, Placebo-Controlled,

Double-Blind Study of Upadacitinib, a Selective

JAK1 Inhibitor, in Japanese Patients with Active

Rheumatoid Arthritis and Inadequate Response

to Conventional Synthetic DMARDs

Safety and Efficacy of Tofacitinib, an Oral Janus

Kinase Inhibitor, up to 36 Months in Patients with

Active Psoriatic Arthritis: Data from the Third

Interim Analysis of OPAL BALANCE, an Open-

Label, Long-Term Extension Study

Tofacitinib in Patients with Psoriatic Arthritis and

Metabolic Syndrome: A Post-Hoc Analysis of

Phase 3 Studies

Changes in Lymphocytes and Lymphocyte

Subsets in Tofacitinib-Treated Patients with

Psoriatic Arthritis

Chairman’s picks

Chairman’s picks


Notes

Saturday, June 16, 2018

POSTER TOURS

Poster Tour S5: Breakout news on non-TNF

biologics in RA

Poster Area – 10:30 - 12:00

SAT0165

Reasons for bDMARD Cessation and Subsequent

Persistence of Second Line Treatment in a Large

Real World Rheumatoid Arthritis Registry

Poster Tour S6: Novel insights on nonbiologics

in RA

Poster Area – 10:30 - 12:00

SAT0217


SAT0218


SAT0219


SAT0220


ABSTRACT ONLY

AB0046


Identification of Distinct Disease Activity

Trajectories in Patients with Rheumatoid Arthritis

Receiving Tofacitinib over 12 Months

Efficacy and Safety of Baricitinib in MTX-IR

Patients with Rheumatoid Arthritis: 52 Week

Results from a Phase 3 Study (RA-BALANCE)

Upadacitinib in Patients with Active Rheumatoid

Arthritis and Inadequate Response or Intolerance

to Biological DMARDs: A Phase 3 Randomized,

Placebo-Controlled, Double-Blind Study of a

Selective JAK1 Inhibitor

Evaluation of Live Zoster Vaccine in a Subset of

Patients with Rheumatoid Arthritis Treated with

Tofacitinib with or without Methotrexate, and

Adalimumab with Methotrexate: Results from a

Phase 3b/4 Randomised Trial

Tofacitinib Impairs Monocyte-Derived Dendritic

Cell Differentiation in Rheumatoid Arthritis and

Psoriatic Arthritis

AB0210

AB0240

AB0258


AB0282

AB0413

AB0425

AB0478

AB0479

AB0482

AB0484

Clinical and Musculoskeletal Ultrasound

Assessment of Therapeutic Response to

Tofacitinib in Patients with Rheumatoid

Arthritis: Real-World Clinical Experience from

a Single Center in Hong Kong

Reduction in Fatigue and Pain are Associated with

Improved Work Productivity in Patients with RA

Impact of Controlling Disease Activity on

Regaining Normal Physical Function, and

Achieving No or Limited Pain in Patients with

Rheumatoid Arthritis Treated with Baricitinib

Adjusting the Dose of Tofacitinib to Achieve

Optimal Results in the Management of Patients

with Active Rheumatoid Arthritis (RA) May

Offer More Successful Results than Utilizing a

Standard Fixed One Dose Approach

Nodular Polyarteritis as an Unforeseeable Adverse

Reaction in RA Patient Treated with Tofacitinib

Prevalence and Risk Factors of Serious

Infections in Rheumatoid Arthritis Patients

Receiving the Biologic/Targeted Synthetic

DMARDs: A Propensity Score Analysis from the

Hong Kong Biologics Registry

Mild and Moderate Hepatic Impairment Have

No Clinically Relevant Impact on Upadacitinib

Pharmacokinetics: Results from a Dedicated

Phase 1 Study

Characterization of the Effect of Renal

Impairment on Upadacitinib Pharmacokinetics

Similar Efficacy of Tofacitinib on Disease

Activity in Rheumatoid Arthritis Patients with

and without Previous Biologicals; Results from

the Turkbio Registry

Monotherapy with Filgotinib, A JAK1-Selective

Inhibitor, Reduces Disease Severity and Alters

Immune Cell Subsets in the NZB/W F1 Murine

Model of Lupus

AB0485


AB0489


AB0492

AB0495

AB0497

AB0500

AB0502

AB0902


AB0920

AB0921


Comparative Efficacy of Tofacitinib and Biologic

DMARDs in Patients with Rheumatoid Arthritis

with Insufficient Response to Subcutaneous

Methotrexate in Clinical Practice

Tofacitinib Improves Left Ventricular Mass and

Cardiac Output in Rheumatoid Arthritis Patients

with Chronic Heart Failure

JAK-Inhibition with Peficitinib and Filgotinib in

Fibroblast-Like Synoviocytes in Rheumatoid Arthritis

Post-Marketing Surveillance of Tofacitinib in

Japanese Patients with Rheumatoid Arthritis: An

Interim Report of Safety Data

Effectiveness, Tolerability, and Safety of

Tofacitinib in Rheumatoid Arthritis: A

Retrospective Analysis of Real-World Data from

the St. Gallen And Aarau Cohort

Efficacy and Safety of Tofacitinib (Tof) in

Patients with Rheumatoid Arthritis at 52 Weeks

in Clinical Practice

Drug Survival Analysis of Tofacitinib in Patients

with Rheumatoid Arthritis

Efficacy of Tofacitinib by Background

Methotrexate Dose in Patients with Psoriatic

Arthritis: A Post-Hoc Analysis of Pooled Data

from 2 Phase 3 Trials

Tumor Necrosis Factor Inhibitors Persistence in

Psoriatic Arthritis Patients

Impact of Baseline Demographics, Disease

Activity and Concomitant Medication on

American College of Rheumatology 20 Response

Rate and Health Assessment Questionnaire-

Disability Index Score with Tofacitinib in Active

Psoriatic Arthritis: A Pooled Subgroup Analysis of

2 Phase 3 Studies

Chairman’s picks

Chairman’s picks


Register for all this FREE content at

www.cytokinesignalling.com

www.cytokinesignalling.com

info@cytokinesignalling.com

@CytokineForum

lnkd.in/PyqQPm

Supported by an unrestricted educational grant from Pfizer Italia S.R.L. and Lilly.

Developed under the auspices of the

University of Glasgow

More magazines by this user
Similar magazines